CMP: ₹ 469

Target: ₹ 510 (9%) Target Period: 12 months

Research

August 4, 2020

Carvaan weakness an overhang...

Saregama India's revenues for Q1FY21 fell 39.2% YoY to ₹ 76.5 crore due to *Carvaan* sales declining to 15,000 units vs. 219,000 in Q1FY20 as retail stores were shut during lockdown. EBITDA came in at ₹ 18.9 crore, up ~16x YoY, due to lower promotion costs (high marketing expense in base quarter) and reduced production costs and contract manufacturing charges with EBITDA margins at 24.7%. Consequently, PAT was at ₹ 15.8 crore.

Carvaan sales drop; strong licensing revenue outlook

Carvaan (B2C) sales dipped to 15,000 units in Q1FY21 as sales through retail network dropped to almost nil. Majority of sales were registered via digital platforms in June. Saregama reiterated their stance of reducing marketing spends and relying on natural pull in demand from the market coupled with festive demand. We build in 0.5 million (mn) and 0.7 mn units in FY21 and FY22, respectively, for Carvaan and expect -5.5% CAGR in revenues in FY20-22 to ₹ 180 crore. Saregama aims to make *Carvaan* a platform with ad monetisation in 18-24 months by offering podcasts. The management has maintained guidance for 15-20% growth in licensing revenue (B2B) for FY21 as content consumption remains robust. The public performance/concerts revenue, however, could drop to zero in FY21. Saregama will invest heavily in music acquisition over the next three years. The company will invest ₹ 200 crore over the next few years with focus on new film music and nonfilm regional music. It has an ambitious target to garner 20% + share in new music acquisition market (currently at ~₹ 400 crore, annually). We estimate 20% CAGR in B2B music sales in FY20-22 to ₹ 349 crore.

TV, movies shoots resumption to aid revenues recovery...

Saregama's film & TV serial shoots, which came to a halt during lockdown, have resumed in July. During lockdown, TV segment witnessed almost nil revenues. Delayed productions of TV & films segment resulted in reduced working capital. On the web series front, the management remains hopeful of a release in FY21E. Saregama has received two new films deal and shoots have started. The company maintained its plan to build a portfolio of small budget profitable films in the next two to three years. We bake in 5.5% CAGR in TV & movies in FY20-22 to ₹ 78 crore, with 8% revenue decline in FY21, to be followed by 20% revenue growth in FY22 on a low base.

Valuation & Outlook

Saregama's key revenue growth driver remains the B2B segment. Increasing content consumption augurs well for the segment with IP monetisation being key. Revenues through licensing deals with Spotify & Facebook have started to kick in. Saregama's strategy to develop *Carvaan* as a platform and its monetisation through ad/subscription revenue could provide long term visibility. However, subdued *Carvaan* sales and delay in its pickup, in the interim, is likely to remain an overhang. Therefore, we maintain **HOLD** rating on the stock with a revised target price of ₹ 510/share at 13x FY22 P/E.



Particulars Particular Amount Market Capitalization 816.5 Total Debt (FY20) ₹9.2 Crore Cash & Investments (FY20) ₹108.5 C rore ΕV ₹741.3 Crore 52 week H/L 540/185 Equity capital (? crore) 17.4 Face value 10.0

Price Performance



Key Highlights

- Music segment declined 37% YoY in the quarter with sharp decline in Carvaan Sales, which impacted revenues while sharp de-growth of 59% in TV & films was on account of no fresh content
- Maintain HOLD with revised target price of ₹ 510/share

Research Analyst

Bhupendra Tiwary, CFA bhupendra.tiwary@icicisecurities.com

| Key Financial Summary | | | | | | | |
|-----------------------|-------|-------|-------|-------|-------|-----------------|--|
| (Year-end March) | FY18 | FY19 | FY20 | FY21E | FY22E | CAGR (FY20-22E) | |
| Net Sales (₹crore) | 356.6 | 544.7 | 521.5 | 483.7 | 613.2 | 8.4 | |
| EBITDA (₹crore) | 36.2 | 38.2 | 60.5 | 70.0 | 88.3 | 20.8 | |
| Net Profit (₹crore) | 28.3 | 54.3 | 43.9 | 54.0 | 68.0 | 24.4 | |
| EPS (₹) | 16.3 | 31.2 | 25.2 | 31.0 | 39.1 | | |
| P/E (x) | 28.9 | 15.0 | 18.6 | 15.1 | 12.0 | | |
| Price / Book (x) | 2.1 | 1.9 | 2.0 | 1.8 | 1.6 | | |
| EV/EBITDA (x) | 18.5 | 19.0 | 12.3 | 9.7 | 7.3 | | |
| RoCE (%) | 9.4 | 16.5 | 14.7 | 15.4 | 16.8 | | |
| RoE (%) | 7.4 | 12.7 | 11.0 | 11.9 | 13.1 | | |

oany Update

Conference Call Highlights

- *Carvaan* sales impacted by lockdown: The management said that *Carvaan* sales in Q1 were affected by retail stores being shut and majority of sales being through e-commerce platforms. The management declined to give guidance for *Carvaan* sales in FY21 and said they are hopeful of a pick-up in sales once the situation normalises. They maintained a cautious approach towards Carvaan and added that marketing spend on *Carvaan* will be lower and they will rely on natural pull in demand from market. Also, the management expects *Carvaan*, as a platform to start generating ad revenue in 18-24 months as it believes podcast consumption will be big in future. The management said *Carvaan* is not a loss making product although profits in FY21 are likely to be minimal
- Licensing to drive revenues: The management maintained their guidance for 15-20% YoY growth in licensing revenue for FY21, driven by growth in OTT platforms as consumption per day is increased. They said Saregama's licensing revenue growth in the last three years at 22% CAGR was almost double the industry average. Also, ₹ 200 crore will be invested over the next three years for music acquisition. It aims to garner 20% + share in the new music acquisition market, which is ~₹ 400 crore, annually. The management said their focus will be regional non-film music in the coming years in languages like Punjabi, Gujarati, Bhojpuri, etc. Saregama modified their content acquisition models and adopted the same model for film and non-film music. The management said 30% of licensing revenue comes from music acquired from films in 21st century. Also, the Spotify & Facebook deals became operational in the quarter
- Film & TV shoots resume: The management said film & TV serial shoots, which were stopped during lockdown, have resumed in July. During lockdown, the company signed agreements to monetise older Tamil content through licensing deals for remake/dubbing. The management said they remain hopeful of a web series release in FY21. On the films front, while the segment suffered losses in the first year, it made marginal profits in the second year. The management said though they give streaming rights to a particular platform for a fixed period, they retain music and other rights. Saregama recognises respective cost and revenues associated with films in the first year itself
- Increased cash & cash equivalent: Saregama has reduced working capital by ₹ 35 crore in the quarter. The company said production linked expenses such as content shoot and manufacturing expenses will go up from Q2FY21 onwards. The company has cash & cash equivalents of ₹ 45 crore

Financial summary

| Exhibit 1: Profit and loss sta | atement | | रै | crore |
|----------------------------------|---------|-------|-------|-------|
| (₹Crore) | FY19 | FY20 | FY21E | FY22E |
| Total operating Incom e | 544.7 | 521.5 | 483.7 | 613.2 |
| Growth (%) | 52.8 | -4.3 | -7.2 | 26.8 |
| Contract manufacturing charg | 221.6 | 107.0 | 83.1 | 129.6 |
| Cost of production of TV , Films | 48.8 | 54.1 | 50.0 | 62.6 |
| Employee Expenses | 56.5 | 66.6 | 71.7 | 78.9 |
| Other Expenses | 179.6 | 233.3 | 208.9 | 253.8 |
| Total Operating Expenditure | 506.6 | 461.0 | 413.7 | 524.9 |
| Adj. EBITDA* | 72.2 | 60.5 | 70.0 | 88.3 |
| Growth (%) | 16.8 | -16.2 | 15.7 | 26.2 |
| Depreciation | 3.3 | 4.6 | 4.8 | 6.1 |
| Interest | 6.6 | 6.7 | 3.8 | 3.8 |
| Other Income* | 22.4 | 11.2 | 12.5 | 13.8 |
| Exceptional Items | - | - | - | - |
| РВТ | 84.7 | 60.4 | 73.8 | 92.2 |
| MI/PAT from associates | | | | |
| Total Tax | 30.4 | 16.9 | 19.8 | 24.2 |
| РАТ | 54.3 | 43.5 | 54.0 | 68.0 |
| Growth (%) | 32.7 | -19.9 | 24.1 | 26.0 |
| EPS (₹) | 31.2 | 25.2 | 31.0 | 39.1 |

| Exhibit 2: Cash flow statem | nent | | ₹ | ₹ crore | |
|-------------------------------|--------|--------|-------|---------|--|
| (Year-end March) | FY19 | FY20 | FY21E | FY22E | |
| Profit after Tax | 54.3 | 43.9 | 54.0 | 68.0 | |
| Add: Depreciation | 3.3 | 4.6 | 4.8 | 6.1 | |
| Add: Interest Paid | 6.6 | 6.7 | 3.8 | 3.8 | |
| (Inc)/dec in Current Assets | -136.2 | 25.1 | 20.7 | -68.6 | |
| Inc/(dec) in CL and Provision | 35.8 | -4.8 | -13.3 | 40.3 | |
| CF from operating activiti | -36.2 | 75.5 | 69.9 | 49.6 | |
| (Inc)/dec in Investments | 0.0 | 0.0 | 0.0 | 0.0 | |
| (Inc)/dec in Fixed Assets | -21.2 | -8.2 | -5.0 | -10.0 | |
| 0 thers | 19.7 | 69.7 | -25.0 | -35.0 | |
| CF from investing activitie | -1.5 | 61.5 | -30.0 | -45.0 | |
| Change in Reserve & Surplus | -8.0 | -73.3 | 0.0 | 0.0 | |
| Inc/(dec) in loan funds | 47.9 | -54.5 | -6.0 | 0.0 | |
| Interest paid | -6.6 | -6.7 | -3.8 | -3.8 | |
| Dividend outflow | 0.0 | 0.0 | 0.0 | 0.0 | |
| 0 thers | 0.4 | -0.3 | 0.0 | 0.0 | |
| CF from financing activitie | 33.7 | -134.8 | -9.8 | -3.8 | |
| Net Cash flow | -4.0 | 2.2 | 30.1 | 0.8 | |
| Opening Cash | 10.8 | 6.8 | 9.0 | 39.1 | |
| Closing Cash | 6.8 | 9.0 | 39.1 | 40.0 | |

Source: Company, ICICI Direct Research * FY19 - adjusted EBITDA for inventory loss for which claim was received and booked in Other income

Source: Company, ICICI Direct Research

| Exhibit 3: Balance sheet | ₹ crore | | | |
|---------------------------|---------|-------|-------|-------|
| (Year-end March) | FY19 | FY20 | FY21E | FY22E |
| Equity Capital | 17.4 | 17.4 | 17.4 | 17.4 |
| Reserve and Surplus | 410.7 | 381.4 | 435.3 | 503.4 |
| Total Shareholders funds | 428.1 | 398.8 | 452.8 | 520.8 |
| Total Debt | 63.8 | 9.2 | 3.2 | 3.2 |
| Minority Interest | 2.6 | 2.3 | 2.3 | 2.3 |
| Deferred Tax Assets | 58.1 | 45.8 | 45.8 | 45.8 |
| Total Liabilities | 552.5 | 456.1 | 504.0 | 572.1 |
| Gross Block | 245.1 | 253.3 | 258.3 | 268.3 |
| Less: Acc Depreciation | 29.9 | 34.5 | 39.4 | 45.5 |
| Net Block | 215.2 | 218.8 | 218.9 | 222.8 |
| Capital WIP | - | | - | - |
| Total Fixed Assets | 215.2 | 218.8 | 218.9 | 222.8 |
| Investments | 148.3 | 75.4 | 100.4 | 135.4 |
| Other non current Assets | 1.6 | 2.8 | 2.8 | 2.8 |
| Debtors | 109.8 | 108.5 | 100.7 | 127.7 |
| Loans and Advances | 5.1 | 5.0 | 4.7 | 5.9 |
| Other Current Assets | 125.7 | 106.6 | 101.6 | 118.9 |
| Cash | 6.8 | 9.0 | 39.1 | 40.0 |
| Inventories | 96.3 | 93.6 | 86.1 | 109.2 |
| Total Current Assets | 343.6 | 322.8 | 332.2 | 401.6 |
| Creditors | 56.5 | 58.0 | 53.0 | 67.2 |
| Provisions | 35.7 | 51.6 | 47.2 | 59.8 |
| Other Current Liabilities | 64.2 | 54.1 | 50.2 | 63.6 |
| Total Current Liabilities | 156.3 | 163.7 | 150.4 | 190.6 |
| Net Current Assets | 187.4 | 159.1 | 181.9 | 211.0 |
| Application of Funds | 552.5 | 456.1 | 504.0 | 572.1 |

| Source: Company, | ICICI Direct Research |
|------------------|-----------------------|
|------------------|-----------------------|

Exhibit 4: Key ratios ₹ crore (Year-end March) FY19 FY20 FY21E FY22E Per share data (₹) EPS 31.2 25.2 39.1 31.0 Cash EPS 33.1 27.9 33.8 42.6 ΒV 245.9 229.1 260.1 299.1 DPS 3.5 1.5 2.0 3.0 Cash Per Share 3.9 5.2 22.5 23.0 **Operating Ratios (%)** Adj. EBITDA Margin 13.2 11.6 14.5 14.4 PBT / Total Operating income 10.7 13.5 13.4 6.4 PAT Margin 10.0 8.4 11.2 11.1 Inventory days 64.5 65.5 65.0 65.0 Debtor days 75.9 76.0 76.0 73.5 37.8 40.0 Creditor days 40.6 40.0 **Return Ratios (%)** 12.7 RoE 11.0 11.9 13.1 RoCE 16.5 14.7 15.4 16.8 RolC 9.6 16.7 19.9 22.8 Valuation Ratios (x) P/E 15.0 18.6 15.1 12.0 EV / EBITDA 19.0 12.3 9.7 7.3 EV / Net Sales 1.3 1.4 1.4 1.1 Market Cap / Sales 1.6 1.7 1.3 1.5 Price to Book Value 0.0 0.0 0.0 0.0 **Solvency Ratios** Debt/EBITDA 1.7 0.2 0.0 0.0 Debt / Equity 0.1 0.0 0.0 0.0 **Current Ratio** 1.7 1.7 1.7 1.9 Quick Ratio 1.3 1.1 1.1 1.1

Source: Company, ICICI Direct Research

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com

ANALYST CERTIFICATION

I/We, Bhupendra Tiwary, CFA < MBA, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities Limited is a SEBI registered Research Analyst with SEBI Registration Number – INH00000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent udgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors and advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or comanaging public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.